Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 1676 - 1700 of 2375 in total
Experimental
Matched Mixtures name: … FLATON ENTERIK DRAJE, 60 ADET …
Experimental
Matched Iupac: … 9-[3-(dimethylamino)propyl]-2-methoxy-9H-thioxanthen-9-ol …
Experimental
Experimental
Matched Iupac: … [(6E,11E)-9-phosphonoheptadeca-6,11-dien-9-yl]phosphonic acid …
A complex mixture of phospholipids; glycolipids; and triglycerides; with substantial amounts of phosphatidylcholines; phosphatidylethanolamines; and phosphatidylinositols, which are sometimes loosely termed as 1,2-diacyl-3-phosphocholines. Lecithin is a component of the cell membrane and commercially extracted from soybeans and egg yolk. The emulsifying and surfactant properties are useful in food additives and...
Experimental
Matched Mixtures name: … Protect Plus SO 60
NDX-3315 is an investigational radiopharmaceutical agent for the diagnosis, treatment monitoring, and management of eosinophilic esophagitis. It is a technetium-99m radiolabeled heparin.
Investigational
99mTc 14F7 Mab has strong anti tumor activity against myeloma cells in vivo. Growth inhibition and prolonged survival of the myeloma tumor were obtained as evidences of anti tumor effect after treatment with 99mTc 14F7 Mab.
Investigational
A recombinant adeno-associated viral vector gene therapy under investigation for the treatment of Menkes disease.
Investigational
Experimental
Matched Mixtures name: … BIOGASTRIN TOZ, 60 G …
Fluocinolone has been used in trials studying the treatment and prevention of Candida Infection, Oral Lichen Planus, Macular Degeneration, and Choroidal Neovascularization.
Investigational
Boehringer Ingelheim Pharmaceuticals’ olcegepant (BIBN 4096) is a selective Calcitonin Gene-Related Peptide (CGRP) antagonist, a new class of drugs in development for the treatment of acute migraine attacks. Olcegepant is undergoing phase II trials in Europe and the US, with preliminary results suggesting that CGRP antagonists may represent a potential...
Investigational
Experimental
Renvistobart is under investigation in clinical trial NCT02913313 (A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors).
Investigational
An isoflavonoid derived from soy products. It inhibits protein-tyrosine kinase and topoisomerase-II (DNA topoisomerases, type II) activity and is used as an antineoplastic and antitumor agent. Experimentally, it has been shown to induce G2 phase arrest in human and murine cell lines. Additionally, genistein has antihelmintic activity. It has been...
Investigational
Matched Mixtures name: … OSMEGA 600 MG/400 IU/25 MG EFERVESAN TABLET, 60 ADET …
Sepantronium is a compound that suppresses survivin expression in a dose and time-dependent manner, and causes broad-range apoptosis.
Investigational
PEN-866 is under investigation in clinical trial NCT03221400 (PEN-866 in Patients With Advanced Solid Malignancies).
Investigational
Investigational
Matched Iupac: … )-2,12-bis(acetyloxy)-15-{[(2R,3S)-3-{[(tert-butoxy)carbonyl]amino}-2-hydroxy-5-methylhexanoyl]oxy}-9- …
99mTc-glucarate(GLA) is an agent for non-invasive detection of breast tumours.
Investigational
Displaying drugs 1676 - 1700 of 2375 in total